Substituted dienes prepared from betulinic acid - Synthesis, cytotoxicity, mechanism of action, and pharmacological parameters
Language English Country France Media print-electronic
Document type Journal Article
PubMed
34311159
DOI
10.1016/j.ejmech.2021.113706
PII: S0223-5234(21)00555-9
Knihovny.cz E-resources
- Keywords
- Apoptosis, Betulinic acid, Cancer, Cell cycle, Cytotoxicity, Mechanism of action, Selectivity, Triterpene, Wittig reaction,
- MeSH
- Alkadienes chemical synthesis chemistry pharmacology MeSH
- Antineoplastic Agents chemical synthesis chemistry pharmacology MeSH
- Apoptosis drug effects MeSH
- Cell Cycle drug effects MeSH
- Cells, Cultured MeSH
- Betulinic Acid MeSH
- Drug Screening Assays, Antitumor MeSH
- Humans MeSH
- Molecular Structure MeSH
- Pentacyclic Triterpenes chemistry pharmacology MeSH
- Cell Proliferation drug effects MeSH
- Dogs MeSH
- Dose-Response Relationship, Drug MeSH
- Structure-Activity Relationship MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Dogs MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Alkadienes MeSH
- Antineoplastic Agents MeSH
- Betulinic Acid MeSH
- Pentacyclic Triterpenes MeSH
A set of new substituted dienes were synthesized from betulinic acid by its oxidation to 30-oxobetulinic acid followed by the Wittig reaction. Cytotoxicity of all compounds was tested in vitro in eight cancer cell lines and two noncancer fibroblasts. Almost all dienes were more cytotoxic than betulinic acid. Compounds 4.22, 4.30, 4.33, 4.39 had IC50 below 5 μmol/L; 4.22 and 4.39 were selected for studies of the mechanism of action. Cell cycle analysis revealed an increase in the number of apoptotic cells at 5 × IC50 concentration, where activation of irreversible changes leading to cell death can be expected. Both 4.22 and 4.39 led to the accumulation of cells in the G0/G1 phase with partial inhibition of DNA/RNA synthesis at 1 × IC50 and almost complete inhibition at 5 × IC50. Interestingly, compound 4.39 at 5 × IC50 caused the accumulation of cells in the S phase. Higher concentrations of tested drugs probably inhibit more off-targets than lower concentrations. Mechanisms disrupting cellular metabolism can induce the accumulation of cells in the S phase. Both compounds 4.22 and 4.39 trigger selective apoptosis in cancer cells via intrinsic pathway, which we have demonstrated by changes in the expression of the crucial apoptosis-related protein. Pharmacological parameters of derivative 4.22 were superior to 4.39, therefore 4.22 was the finally selected candidate for the development of anticancer drug.
References provided by Crossref.org